drugset / Trial / NCT06383572
Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies
NaSingle-groupOpen-labelTreatment
Summary
To find a recommended dose of PRAME-TCR-NK cells that can be given to patients with AML or MDS.
Timeline
- Start
- 2024-06-26
- Primary completion
- 2027-04-01
- Completion
- 2029-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Cyclophosphamide | Other / unclassified | — | Intravenous |
| Background | Decitabine | Small molecule | — | Intravenous |
| Background | Dexamethasone | Small molecule | — | Oral |
| Background | Fludarabine | Small molecule | — | Intravenous |